These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 32748638)
1. Canagliflozin and cardiovascular outcomes in Type 2 diabetes. Sarraju A; Spencer-Bonilla G; Rodriguez F; Mahaffey KW Future Cardiol; 2021 Jan; 17(1):39-48. PubMed ID: 32748638 [TBL] [Abstract][Full Text] [Related]
2. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes. Handelsman Y Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707 [TBL] [Abstract][Full Text] [Related]
3. Class effects of SGLT2 inhibitors on cardiorenal outcomes. Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965 [TBL] [Abstract][Full Text] [Related]
4. Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results. Weir MR; McCullough PA; Buse JB; Anderson J Am J Nephrol; 2020; 51(4):276-288. PubMed ID: 32172239 [TBL] [Abstract][Full Text] [Related]
6. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science. Cruz JE; Ahuja T; Bridgeman MB Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393 [TBL] [Abstract][Full Text] [Related]
7. Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis. Jardine M; Zhou Z; Lambers Heerspink HJ; Hockham C; Li Q; Agarwal R; Bakris GL; Cannon CP; Charytan DM; Greene T; Levin A; Li JW; Neuen BL; Neal B; Oh R; Oshima M; Pollock C; Wheeler DC; de Zeeuw D; Zhang H; Zinman B; Mahaffey KW; Perkovic V Clin J Am Soc Nephrol; 2021 Mar; 16(3):384-395. PubMed ID: 33619120 [TBL] [Abstract][Full Text] [Related]
9. Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population. Wittbrodt ET; Eudicone JM; Bell KF; Enhoffer DM; Latham K; Green JB Am J Manag Care; 2018 Apr; 24(8 Suppl):S138-S145. PubMed ID: 29693360 [TBL] [Abstract][Full Text] [Related]
10. [In patients with type 2 diabetes and diabetic nephropathy with albuminuria, what is the effect of SGLT2 inhibitor canagliflozin on renal and cardiovascular outcomes?]. Lanthier L; Huard G; Plourde MÉ; Cauchon M Rev Med Interne; 2020 Jan; 41(1):67-68. PubMed ID: 31812446 [No Abstract] [Full Text] [Related]
11. Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. Jardine MJ; Zhou Z; Mahaffey KW; Oshima M; Agarwal R; Bakris G; Bajaj HS; Bull S; Cannon CP; Charytan DM; de Zeeuw D; Di Tanna GL; Greene T; Heerspink HJL; Levin A; Neal B; Pollock C; Qiu R; Sun T; Wheeler DC; Zhang H; Zinman B; Rosenthal N; Perkovic V; J Am Soc Nephrol; 2020 May; 31(5):1128-1139. PubMed ID: 32354987 [TBL] [Abstract][Full Text] [Related]
12. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function. Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Desai M; Li Q; Deng H; Rosenthal N; Jardine MJ; Bakris G; Perkovic V Circulation; 2018 Oct; 138(15):1537-1550. PubMed ID: 29941478 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data. Davies MJ; Merton K; Vijapurkar U; Yee J; Qiu R Cardiovasc Diabetol; 2017 Mar; 16(1):40. PubMed ID: 28327140 [TBL] [Abstract][Full Text] [Related]
14. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors. Scheen AJ Circ Res; 2018 May; 122(10):1439-1459. PubMed ID: 29748368 [TBL] [Abstract][Full Text] [Related]
15. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis. Lo KB; Gul F; Ram P; Kluger AY; Tecson KM; McCullough PA; Rangaswami J Cardiorenal Med; 2020; 10(1):1-10. PubMed ID: 31743918 [TBL] [Abstract][Full Text] [Related]
16. What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors? Sridhar VS; Rahman HU; Cherney DZI Diabetes Obes Metab; 2020 Apr; 22 Suppl 1():55-68. PubMed ID: 32267075 [TBL] [Abstract][Full Text] [Related]
18. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial. Neal B; Perkovic V; Matthews DR; Mahaffey KW; Fulcher G; Meininger G; Erondu N; Desai M; Shaw W; Vercruysse F; Yee J; Deng H; de Zeeuw D; Diabetes Obes Metab; 2017 Mar; 19(3):387-393. PubMed ID: 28120497 [TBL] [Abstract][Full Text] [Related]
19. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus. Carlson CJ; Santamarina ML Expert Opin Drug Saf; 2016 Oct; 15(10):1401-12. PubMed ID: 27449721 [TBL] [Abstract][Full Text] [Related]
20. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association. Lee S Crit Pathw Cardiol; 2017 Sep; 16(3):93-95. PubMed ID: 28742644 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]